Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: NuvaRing
NuvaRing is a combined hormonal contraceptive vaginal ring that releases etonogestrel and ethinyl estradiol. It is placed in the vagina for three weeks, followed by a one-week ring-free interval during which withdrawal bleeding typically occurs. It belongs to the class of combined hormonal contraceptives and works by preventing ovulation, thickening cervical mucus, and thinning the uterine lining, making it difficult for sperm to reach an egg and for a fertilized egg to implant.
For contraception to prevent pregnancy.
Cigarette smoking increases the risk of serious cardiovascular side effects from hormonal contraceptive use, including NuvaRing. Women over 35 who smoke should not use NuvaRing.
Outcome:
Decreased contraceptive efficacy
Mechanism:
Induction of hepatic enzymes
Outcome:
Potentially decreased contraceptive efficacy with chronic high doses
Mechanism:
Hepatic metabolism
Outcome:
May slightly increase estrogen levels
Mechanism:
Altered metabolism
Most likely new formulation: Biodegradable vaginal ring (2028, 70% confidence)
Based on current usage trends and clinical trial data, there is a 95% likelihood that NuvaRing will maintain its current regulatory status for the next 5 years.
Hormonal Contraceptive, Combined
Steroid